For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Neuropeptides

Cerebrolysin research peptide

Cerebrolysin is described in the literature as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain proteins. It has no single formula or mass.

1 size · from $16.99 · 1 in stock · flat $24.95 US shipping per order

Sizes, prices and availability

Cerebrolysin sizes and prices
SizeSKUStated purityBatch COAPriceAvailability
60 mg CBL60 Not yet provided Not yet provided $16.99 In stock

Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details

About Cerebrolysin

Gevaert et al. (2015) describe Cerebrolysin as a parenteral peptide preparation produced by controlled digestion of porcine brain proteins, an approved nootropic medicine in some countries that is also available on the Internet, and report that its exact chemical composition had been unknown. Using HPLC with ion-trap MS and UHPLC with quadrupole-ion mobility-time-of-flight MS, with a UniProt pig protein database search and de novo sequencing, they identified 638 unique peptides in an Internet-obtained sample, mainly from tubulin alpha and beta chains, actin and myelin basic protein, and found no fragments of GDNF, NGF, BDNF or CNTF. Gromova et al. (2019) used orbital ion-trap MS with de novo sequencing on a light peptide fraction and report 14,635 peptide sequences corresponding to 1,643 porcine neuronal proteins, including 405 fragments that match known bioactive peptides, and report the presence of Leu- and Met-enkephalins and fragments of orexin, neuropeptide VF, galanin and nerve growth factor. The samples and methods differ between these two papers, and so do the conclusions about neurotrophic factor fragments.

Yang et al. (2023) compared sample preparation for nanoLC-MS of Cerebrolysin and report that mixed-mode cation-exchange extraction with PEAKS sequencing gave the most peptides; they again found peptides from myelin basic protein and tubulin beta chain and, by bioinformatics, flagged LLNLQPPPR, LSPSLRLP and WPFPR as candidate functional peptides. Seidl and Aigner (2024) analysed the peptide composition and neurotrophic activity of several preparations described as similar to Cerebrolysin and report that their composition differed significantly from Cerebrolysin. For clinical-trial design, the Cochrane review by Ziganshina et al. (2023) covers randomised trials of Cerebrolysin or Cerebrolysin-like agents against placebo or no treatment in acute ischaemic stroke, begun within 48 hours of onset: seven trials with 1,773 participants, with the authors rating risk of bias as unclear for several domains. That review is cited for its design only.

What the published literature covers

  • Gevaert et al. (2015) report LC-MS peptide profiling of an Internet-obtained sample (638 peptides).
  • Gromova et al. (2019) report a proteomic analysis of the light peptide fraction (14,635 sequences).
  • Yang et al. (2023) report an optimised nanoLC-MS approach for identifying peptides.
  • Seidl and Aigner (2024) report a composition and activity comparison with other brain-derived peptide preparations.
  • Ziganshina et al. (2023) is a Cochrane review of randomised trials in acute ischaemic stroke (design only here).

Vial arithmetic

The peptide reconstitution calculator converts a vial size, diluent volume and target amount into concentration, syringe units and draws per vial. Volumes convert to syringe units with the syringe units converter. It does arithmetic only and does not suggest any amount.

FAQ

What is Cerebrolysin?

A mixture of low-molecular-weight peptides and amino acids derived from porcine brain proteins (Ziganshina et al., 2023; Gevaert et al., 2015). It is not a single peptide.

Does it have a molecular weight or formula?

No. Mass spectrometry finds hundreds to thousands of peptides: 638 in one Internet-obtained sample (Gevaert et al., 2015) and 14,635 sequences in a light peptide fraction (Gromova et al., 2019).

How is identity assessed for a mixture?

By peptide profiling, such as LC-MS with database search and de novo sequencing, and by comparison with a reference. The literature reports that preparations described as similar can differ significantly in composition (Seidl and Aigner, 2024).

What should a buyer ask the supplier?

What the 60 mg listing consists of, how the batch was characterised, and for the documentation to show a peptide profile and not one mass. This site shows the COA as not yet provided until a document exists.

What sizes of Cerebrolysin does Covalume list?

Covalume lists Cerebrolysin in one size: 60 mg. Each size shows its price and live stock status in the variants table on this page.

How is the purity of Cerebrolysin documented?

Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.

References

  1. Gevaert B, D'Hondt M, Bracke N, et al. (2015). Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. Drug Test Anal 7:835-42. PubMed 26017115 · DOI
  2. Gromova OA, Torshin IY, Zgoda VG, et al. (2019). [An analysis of the peptide composition of a 'light' peptide fraction of cerebrolysin]. Zh Nevrol Psikhiatr Im S S Korsakova 119:75-83. PubMed 31626174 · DOI
  3. Yang B, Li Y, Guo W, et al. (2023). Optimized approach for active peptides identification in Cerebrolysin by nanoLC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 1225:123755. PubMed 37220681 · DOI
  4. Seidl LF, Aigner L (2024). Comparing the biological activity and composition of Cerebrolysin with other peptide preparations. J Med Life 17:24-27. PubMed 38737662 · DOI
  5. Ziganshina LE, Abakumova T, Nurkhametova D, et al. (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 10:CD007026. PubMed 37818733 · DOI

Identity values are from PubChem and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-19.

Related research peptides

From the research library